| Literature DB >> 24223738 |
Xiao Chen1, Yu Chen, Qing Yang, Haishen Kong, Fei Yu, Dongsheng Han, Shufa Zheng, Dawei Cui, Lanjuan Li.
Abstract
BACKGROUND: Plesiomonas shigelloides can cause gastroenteritis and extra-intestinal diseases in humans. However, the prevalence of P. shigelloides infections has not been investigated in China.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24223738 PMCID: PMC3817182 DOI: 10.1371/journal.pone.0077877
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Prevalence of bacterial pathogens in patients with acute diarrhea and those without diarrhea during the period of March 2010 to May 2012.
| Bacterial isolate | No. (%) of cases |
| |
| Diarrhea (n = 3,536) | Non-diarrheal (n = 478) | ||
| Single infection with | 76 (2.1) | 0 | 0.001 |
|
| 28 (0.8) | 0 | 0.097 |
| Total | 104 (2.9) | 0 | 0.000 |
| Diarrheagenic | 594 (16.8) | 55 (11.5) | 0.003 |
| Enteroaggregative | 363 (10.3) | 30 (6.3) | 0.006 |
| Enterotoxigenic | 115 (3.3) | 12 (2.5) | 0.384 |
| Enteropathogenic | 97 (2.7) | 12 (2.5) | 0.769 |
| Shiga toxin-producing | 15 (0.4) | 0 | 0.304 |
| Enteroinvasive | 4 (0.1) | 1 (0.2) | 0.470 |
|
| 315 (8.9) | 3 (0.6) | 0.000 |
|
| 152 (4.3) | 5 (1.1) | 0.001 |
|
| 57 (1.6) | 0 | 0.005 |
|
| 39 (1.1) | 0 | 0.040 |
|
| 25 (0.7) | 1 (0.2) | 0.332 |
|
| 21 (0.6) | 1 (0.2) | 0.460 |
|
| 17 (0.5) | 1 (0.2) | 0.639 |
Demographic characteristics of patients with Plesiomonas shigelloides infection and acute diarrhea.
| Variable | Category | No. of samples tested | No. (%) of positive samples |
|
| Time | <0.001 | |||
| March to May | 591 | 9 (1.5) | ||
| June to August | 1564 | 69 (4.4) | ||
| September to November | 823 | 24 (2.9) | ||
| December to February | 558 | 2 (0.4) | ||
| Age (years) | <0.001 | |||
| 0–5 | 930 | 8 (0.9) | ||
| 6–18 | 205 | 4 (1.9) | ||
| 19–44 | 1137 | 54 (4.7) | ||
| 45–59 | 837 | 29 (3.5) | ||
| ≥60 | 427 | 9 (2.1) | ||
| Sex | 0.517 | |||
| Male | 1964 | 61 (3.1) | ||
| Female | 1572 | 43 (2.7) |
Symptoms of Plesiomonas shigelloides infection with acute diarrhea.
| Symptoms | No. (%) of cases |
| |
| Singly infected (n = 76) | Co-infected (n = 28) | ||
| Watery diarrhea | 53 (69.7) | 17 (60.7) | 0.384 |
| Bloody diarrhea | 11 (14.5) | 6 (21.4) | 0.581 |
| Visible mucus in stool | 13 (17.1) | 7 (25.0) | 0.365 |
| Fever | 22 (28.9) | 12 (42.9) | 0.180 |
| Vomiting | 9 (11.8) | 5 (17.9) | 0.636 |
| Abdominal pain | 50 (65.8) | 20 (71.4) | 0.587 |
Features of eight patients with Plesiomonas shigelloides extra-intestinal infections.
| No. | Age | Sex | Predisposing factor(s) | Comorbidities | Clinical presentation | Pathogen(s) isolated by specimen cultured | Nosocomia etiology | Drug(s) | Outcome | ||
| years | Disease(s) and/or condition(s) | Procedure(s) | Non-blood | Blood | |||||||
| 1 | 34 | M | None | Chemotherapy | Viral hepatitis B, Non-Hodgkin's lymphoma | Septicemia | ND |
| No | CFP-Sulb | Cured |
| 2 | 68 | F | None | None | Viral hepatitis B-related cirrhosis, ascites | Septicemia | ND |
| Yes | LEV | Cured |
| 3 | 60 | M | Cholelithiasis | ERCP performed 2 days before episode | None | Cholangitis, septicemia | Bile: |
| Yes | IPM | Cured |
| 4 | 71 | F | Cholangitis | None | Hypertension, cholecystectomy 16 years ago | Biliary peritonitis | ND |
| No | LEV, CRO, tinidazole | Cured |
| 5 | 55 | M | Cerebral hemorrhage | Intracerebral hematoma cleared 5 days before episode | Hypertension, hypertensive renal disease | Pulmonary infection | Sputum: | None | Yes | IPM, LEV | Cured |
| 6 | 69 | F | Gallbladder carcinoma | Cholecystectomy complicated with bile leakage, followed by intestinal and biliary drainage operation | None | Septicemia, surgical site infection | Drainage fluid: |
| Yes | CFP-Sulb, IPM, CIP | Cured |
| 7 | 59 | F | Duodenum malignancies | Whipple procedure | None | Surgical site infection | Drainage fluid: | None | Yes | IPM | Cured |
| 8 | 75 | M | Cholelithiasis | Cholecystectomy | Hepatic malignancies | Pulmonary infection | Sputum: | ND | Yes | IPM, CFP-Sulb | Cured |
ERCP, endoscopic retrograde cholangiopancreatography; ND, not done (i.e., specimens were not obtained for culture).
P. shigelloides, Plesiomonas shigelloides; E. coli, Escherichia coli; S. marcescens, Serratia marcescens; S. maltophilia, Stenotrophomonas maltophilia; A. baumannii, Acinetobacter baumannii; K. pneumoniae, Klebsiella pneumoniae; P. aeruginosa, Pseudomonas aeruginosa.
MEM, meropenem; CIP, ciprofloxacin; CFP-Sulb, cefoperazone-sulbactam; LEV, levofloxacin; IPM, imipenem; CRO, ceftriaxone.
Antimicrobial susceptibility of Plesiomonas shigelloides.
| Antimicrobial agent | R% | I% | S% |
| Ampicillin | 91.7 | 4.2 | 4.1 |
| Piperacillin | 7.8 | 14.4 | 77.8 |
| Amoxicillin/Clavulanic acid | 3.2 | 1.1 | 95.7 |
| Cefoperazone/Sulbactam | 0.0 | 3.3 | 96.7 |
| Ampicillin/Sulbactam | 4.4 | 2.2 | 93.4 |
| Piperacillin/Tazobactam | 0.0 | 0.0 | 100.0 |
| Cefazolin | 16.0 | 48.9 | 35.1 |
| Cefuroxime | 3.3 | 1.1 | 95.6 |
| Ceftazidime | 3.1 | 2.1 | 94.8 |
| Cefotaxime | 1.1 | 2.1 | 96.8 |
| Cefepime | 2.1 | 0.0 | 97.9 |
| Cefoxitin | 6.4 | 1.3 | 92.3 |
| Aztreonam | 4.3 | 8.6 | 87.1 |
| Imipenem | 0.0 | 0.0 | 100.0 |
| Meropenem | 0.0 | 0.0 | 100.0 |
| Amikacin | 46.2 | 22.6 | 31.2 |
| Gentamicin | 37.1 | 32.0 | 30.9 |
| Ciprofloxacin | 8.5 | 28.7 | 62.8 |
| Levofloxacin | 3.2 | 0.0 | 96.8 |
| Trimethoprim/Sulfamethoxazole | 41.2 | 3.1 | 55.7 |
| Tetracycline | 4.5 | 8.9 | 86.6 |
R, resistant; I, intermediate; S, susceptible.